Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
Vincenzo Malagnino,
Romina Salpini,
Elisabetta Teti,
Mirko Compagno,
Ludovica Ferrari,
Tiziana Mulas,
Valentina Svicher,
Marta Zordan,
Monica Basso,
Giuliana Battagin,
Sandro Panese,
Maria Cristina Rossi,
Renzo Scaggiante,
Daniela Zago,
Marco Iannetta,
Saverio Giuseppe Parisi,
Massimo Andreoni,
Loredana Sarmati
Affiliations
Vincenzo Malagnino
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Romina Salpini
Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy
Elisabetta Teti
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Mirko Compagno
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Ludovica Ferrari
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Tiziana Mulas
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Valentina Svicher
Department of Biology, Tor Vergata University of Rome, 00133 Rome, Italy
Marta Zordan
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Monica Basso
Department of Molecular Medicina, University of Padua, 35100 Padova, Italy
Giuliana Battagin
UOC Malattie Infettive, Ospedale di Vicenza, 36100 Vicenza, Italy
Sandro Panese
UOC Malattie Infettive, Ospedale di Venezia, 30122 Venezia, Italy
Maria Cristina Rossi
UOC Malattie Infettive, Ospedale di Treviso, 31100 Treviso, Italy
Renzo Scaggiante
UOC Malattie Infettive, Ospedale di Belluno, 32100 Belluno, Italy
Daniela Zago
Department of Molecular Medicina, University of Padua, 35100 Padova, Italy
Marco Iannetta
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Saverio Giuseppe Parisi
Department of Molecular Medicina, University of Padua, 35100 Padova, Italy
Massimo Andreoni
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
Loredana Sarmati
Clinical of Infectious Diseases, Tor Vergata Policlinic of Rome, 00133 Rome, Italy
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35–14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC.
